Healio

UBX1325 fails to meet primary analysis endpoint despite vision gains in DME

Please provide your email address to receive an email when new articles are posted on . UBX1325 did not meet statistical noninferiority to aflibercept on the average of weeks 20 and 24. Patients ...
Business Wire

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Narsoplimab-treated patients had an over 2-fold reduction (hazard ratio = 0.42 [95% confidence interval: 0.21, 0.83]) to an over 4-fold reduction (hazard ratio = 0.24 [95% confidence interval: 0.13, 0 ...
ascopubs.org

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell ...

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). This is an ASCO Meeting ...
Seeking Alpha

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing ...
Business Wire

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR ...